Trial · NCT03663712
Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies
NCT03663712, Phase 1, Completed, Dan Blazer III, M.D.; results first posted 2024-11-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies. Trials, record NCT03663712. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03663712
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies
- NCT number
- NCT03663712
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 28 participants, actual
- Lead sponsor
- Dan Blazer III, M.D.
- Conditions
- Peritoneal Surface Malignancy
- Interventions
- Talimogene Laherparepvec
- First posted
- 2018-09-10
- Last updated
- 2024-11-20
- Results first posted
- 2024-11-20
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose Limiting Toxicity (DLT) | from start of treatment until 30-day follow-up visit, up to 14 weeks | Number of participants who experienced a dose limiting toxicity (DLT) |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Dose Limiting Toxicity (DLT) | from start of treatment until 30-day follow-up visit, up to 14 weeks | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Dose Limiting Toxicity (DLT) | TVEC Dose of 4x10^6 PFU (Plaque-forming Units) | 0 | Participants | ||
| Dose Limiting Toxicity (DLT) | TVEC Dose of 4x10^7 PFU (Plaque-forming Units) | 0 | Participants | ||
| Dose Limiting Toxicity (DLT) | TVEC Dose of 4x10^8 PFU (Plaque-forming Units) | 0 | Participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dose Level 1 | 3 | |
| Overall Study | STARTED | Dose Level 2 | 4 | |
| Overall Study | STARTED | Dose Level 3 | 11 | |
| Overall Study | COMPLETED | Dose Level 1 | 3 | |
| Overall Study | COMPLETED | Dose Level 2 | 4 | |
| Overall Study | COMPLETED | Dose Level 3 | 11 | |
| Overall Study | NOT COMPLETED | Dose Level 1 | 0 | |
| Overall Study | NOT COMPLETED | Dose Level 2 | 0 | |
| Overall Study | NOT COMPLETED | Dose Level 3 | 0 |
Source ClinicalTrials.gov
Adverse events63
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Dose Level 1 | 0 | 3 | |
| other | Anemia | Blood and lymphatic system disorders | Dose Level 2 | 0 | 4 | |
| other | Anemia | Blood and lymphatic system disorders | Dose Level 3 | 2 | 11 | |
| other | Abdominal pain | Gastrointestinal disorders | Dose Level 1 | 2 | 3 | |
| other | Abdominal pain | Gastrointestinal disorders | Dose Level 2 | 1 | 4 | |
| other | Abdominal pain | Gastrointestinal disorders | Dose Level 3 | 8 | 11 | |
| other | Constipation | Gastrointestinal disorders | Dose Level 1 | 1 | 3 | |
| other | Constipation | Gastrointestinal disorders | Dose Level 2 | 0 | 4 | |
| other | Constipation | Gastrointestinal disorders | Dose Level 3 | 1 | 11 | |
| other | Nausea | Gastrointestinal disorders | Dose Level 1 | 0 | 3 |
1 to 10 of 63Source ClinicalTrials.gov
See all 63 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dose Level 1 | 3 | 3 |
| Total, all-cause mortality | Dose Level 2 | 4 | 4 |
| Total, all-cause mortality | Dose Level 3 | 5 | 11 |
| Total, other adverse events | Dose Level 1 | 3 | 3 |
| Total, other adverse events | Dose Level 2 | 3 | 4 |
| Total, other adverse events | Dose Level 3 | 10 | 11 |
| Total, serious adverse events | Dose Level 1 | 1 | 3 |
| Total, serious adverse events | Dose Level 2 | 2 | 4 |
| Total, serious adverse events | Dose Level 3 | 3 | 11 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03663712
GET https://conductscience.org/api/trials/v1/NCT03663712/events?page=2